pubmed search derived

{
  "input": {
    "body": {
      "limit": 2,
      "query": "GLP-1 obesity"
    },
    "type": "http",
    "method": "POST",
    "bodyType": "json"
  },
  "output": {
    "type": "json",
    "example": {
      "query": "GLP-1 obesity",
      "total": 11811,
      "source": "NCBI PubMed E-utilities",
      "results": [
        {
          "doi": "10.1016/j.medcli.2025.107035",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40466247/",
          "pmid": "40466247",
          "title": "GLP-1-based medications: Mechanisms involved in obesity treatment.",
          "authors": [
            "Salvador J"
          ],
          "journal": "Medicina clinica",
          "pubDate": "2025 Jul",
          "abstract": "Thanks to biochemical engineering, the glucagon-like peptide-1 (GLP-1) molecule has emerged as an essential element in the development of diverse agonists and multiagonists, based in the GLP-1 structure for obesity treatment. These new antiobesity medications can reach up to 24% weight loss, which makes possible an effective management of obesity and its complications. GLP-1 agonists affect divers…"
        },
        {
          "doi": "10.1016/j.molmet.2021.101351",
          "url": "https://pubmed.ncbi.nlm.nih.gov/34626851/",
          "pmid": "34626851",
          "title": "GLP-1 physiology informs the pharmacotherapy of obesity.",
          "authors": [
            "Drucker DJ"
          ],
          "journal": "Molecular metabolism",
          "pubDate": "2022 Mar",
          "abstract": "Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-dependent insulin release and reduce glucagon secretion and gastric emptying, enabling their successful development for the treatment of type 2 diabetes (T2D). These agents also inhibit food intake and reduce body weight, fostering investigation of GLP1RA for the treatment of obesity. Here I discuss the physiology of Glucagon-like …"
        }
      ]
    }
  }
}